sales@fnfresearch.comTel: +86 21 80360450 | USA: +1-347-989-3985

Search Market Research Report

Home / Healthcare / Urinary Tract Infection Therapeutics

Urinary Tract Infection Therapeutics Market By Age Group (Adults, Elderly, and Children), by Indication (Uncomplicated, Recurrent, Complicated, and Catheter Associated), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and by Drug Type (Quinolones, Azoles & Amphotericin B, Aminoglycoside, Penicillin & Combinations, Cephalosporin, Nitrofurans, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019–2027

  • Publish On: Sep-2019
  • Total Pages: 110
  • Report Code: FAF-75
  • Base Year: 2018
  • Format:

Industry Insights

The report covers a forecast and an analysis of the urinary tract infection therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the urinary tract infection therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the urinary tract infection therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the urinary tract infection therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the urinary tract infection therapeutics market by segmenting it based on age group, indication, distribution channel, drug type, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The major growth driver of the urinary tract infection therapeutics market is the escalating incidences of UTI infections. As women have shorter urethras, they are more at risk of being infected than men. The market for urinary tract infection therapeutics is also driven by the growing elderly population, particularly above 60 and above, across the world.
The age group segment of the market comprises adults, elderly, and children. Based on indication, the market includes uncomplicated, complicated, catheter-associated, and recurrent. By distribution channel, the market is categorized into e-commerce, hospital pharmacies, and retail pharmacies. On the basis of drug type, the market is fragmented into Nitrofurans, Azoles & Amphotericin B, Cephalosporin, Quinolones, Penicillin & Combinations, Aminoglycoside, and others.

Global Urinary Tract Infection Therapeutics : Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Key Features of Urinary Tract Infection Therapeutics Report:

  • Urinary Tract Infection Therapeutics structure: Overview, industry life cycle analysis, supply chain analysis
  • Urinary Tract Infection Therapeutics : Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
  • Urinary Tract Infection Therapeutics size, trend, and forecast analysis
  • Urinary Tract Infection Therapeutics segments’ trend and forecast
  • Urinary Tract Infection Therapeutics ’s competitive landscapes: Market share, Product portfolio, New product launches, etc.
  • Urinary Tract Infection Therapeutics attractiveness and associated growth opportunities
  • Emerging trends in the Urinary Tract Infection Therapeutics .
  • Strategic growth opportunities for the existing and new players
  • Key success factors

Benefits of Buying from Facts & Factors:

  • Our proven methodologies and systematic analysis help in making confident business and strategic decisions.
  • A market study that conducts at Facts & Factors Market Research can save significant cost and time, and can help prevent making costly mistakes.

Table of Content

  • Chapter 1. Executive Summary 26
  • Chapter 2. Urinary Tract Infection Therapeutics market - Age Group Analysis 28
    • 2.1. Global Urinary Tract Infection Therapeutics Market - Age Group Overview 28
    • 2.2. Global Urinary Tract Infection Therapeutics Market Share, by Age Group, 2018 & 2025 (USD Million) 28
    • 2.3. Adults 30
      • 2.3.1. Global Adults Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 30
    • 2.4. Elderly 31
      • 2.4.1. Global Elderly Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 31
    • 2.5. Children 32
      • 2.5.1. Global Children Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 32
  • Chapter 3. Urinary Tract Infection Therapeutics market - Indication Analysis 32
    • 3.1. Global Urinary Tract Infection Therapeutics Market - Indication Overview 32
    • 3.2. Global Urinary Tract Infection Therapeutics Market Share, by Indication, 2018 & 2025 (USD Million) 33
    • 3.3. Uncomplicated UTI 34
      • 3.3.1. Global Uncomplicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 34
    • 3.4. Recurrent UTI 35
      • 3.4.1. Global Recurrent UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 35
    • 3.5. Complicated UTI 36
      • 3.5.1. Global Complicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 36
    • 3.6. CA (Catheter Associated) UTI 37
      • 3.6.1. Global CA (Catheter Associated) UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 37
  • Chapter 4. Urinary Tract Infection Therapeutics market - Drug Type Analysis 37
    • 4.1. Global Urinary Tract Infection Therapeutics Market - Drug Type Overview 37
    • 4.2. Global Urinary Tract Infection Therapeutics Market Share, by Drug Type, 2018 & 2025 (USD Million) 38
    • 4.3. Quinolones 40
      • 4.3.1. Global Quinolones Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 40
    • 4.4. Azoles & Amphotericin B 41
      • 4.4.1. Global Azoles & Amphotericin B Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 41
    • 4.5. Aminoglycoside 42
      • 4.5.1. Global Aminoglycoside Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 42
    • 4.6. Penicillin & Combinations 43
      • 4.6.1. Global Penicillin & Combinations Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 43
    • 4.7. Cephalosporin 44
      • 4.7.1. Global Cephalosporin Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 44
    • 4.8. Nitrofurans 45
      • 4.8.1. Global Nitrofurans Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 45
    • 4.9. Others 46
      • 4.9.1. Global Others Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 46
  • Chapter 5. Urinary Tract Infection Therapeutics market - Distribution Channel Analysis 46
    • 5.1. Global Urinary Tract Infection Therapeutics Market - Distribution Channel Overview 46
    • 5.2. Global Urinary Tract Infection Therapeutics Market Share, by Distribution Channel, 2018 & 2025 (USD Million) 47
    • 5.3. Hospital Pharmacies 48
      • 5.3.1. Global Hospital Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 48
    • 5.4. Retail Pharmacies 49
      • 5.4.1. Global Retail Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 49
    • 5.5. E-commerce 50
      • 5.5.1. Global E-commerce Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 50
  • Chapter 6. Urinary Tract Infection Therapeutics market - Regional Analysis 51
    • 6.1. Global Urinary Tract Infection Therapeutics Market Regional Overview 51
    • 6.2. Global Urinary Tract Infection Therapeutics Market Share, by Region, 2018 & 2025 (Value) 51
    • 6.3. North America 53
      • 6.3.1. North America Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 53
      • 6.3.2. North America Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 53
      • 6.3.3. North America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 55
        • 6.3.3.1. North America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 55
      • 6.3.4. North America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 56
        • 6.3.4.1. North America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 56
      • 6.3.5. North America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 57
        • 6.3.5.1. North America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 57
      • 6.3.6. North America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 58
        • 6.3.6.1. North America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 58
      • 6.3.7. U.S. 59
        • 6.3.7.1. U.S. Market size and forecast, 2016-2026 (USD Million) 59
      • 6.3.8. Rest of North America 60
        • 6.3.8.1. Rest of North America Market size and forecast, 2016-2026 (USD Million) 60
    • 6.4. Europe 61
      • 6.4.1. Europe Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 61
      • 6.4.2. Europe Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 61
      • 6.4.3. Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 63
        • 6.4.3.1. Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 63
      • 6.4.4. Europe Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 64
        • 6.4.4.1. Europe Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 64
      • 6.4.5. Europe Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 65
        • 6.4.5.1. Europe Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 65
      • 6.4.6. Europe Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 66
        • 6.4.6.1. Europe Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 66
      • 6.4.7. Germany 67
        • 6.4.7.1. Germany Market size and forecast, 2016-2026 (USD Million) 67
      • 6.4.8. France 68
        • 6.4.8.1. France Market size and forecast, 2016-2026 (USD Million) 68
      • 6.4.9. U.K. 69
        • 6.4.9.1. U.K. Market size and forecast, 2016-2026 (USD Million) 69
      • 6.4.10. Italy 70
        • 6.4.10.1. Italy Market size and forecast, 2016-2026 (USD Million) 70
      • 6.4.11. Spain 71
        • 6.4.11.1. Spain Market size and forecast, 2016-2026 (USD Million) 71
      • 6.4.12. Rest of Europe 72
        • 6.4.12.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million) 72
    • 6.5. Asia Pacific 73
      • 6.5.1. Asia Pacific Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 73
      • 6.5.2. Asia Pacific Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 73
      • 6.5.3. Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 75
        • 6.5.3.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 75
      • 6.5.4. Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 76
        • 6.5.4.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 76
      • 6.5.5. Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 77
        • 6.5.5.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 77
      • 6.5.6. Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 78
        • 6.5.6.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 78
      • 6.5.7. China 79
        • 6.5.7.1. China Market size and forecast, 2016-2026 (USD Million) 79
      • 6.5.8. Japan 80
        • 6.5.8.1. Japan Market size and forecast, 2016-2026 (USD Million) 80
      • 6.5.9. India 81
        • 6.5.9.1. India Market size and forecast, 2016-2026 (USD Million) 81
      • 6.5.10. South-East Asia 82
        • 6.5.10.1. South-East Asia Market size and forecast, 2016-2026 (USD Million) 82
      • 6.5.11. Rest of Asia Pacific 83
        • 6.5.11.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million) 83
    • 6.6. Latin America 84
      • 6.6.1. Latin America Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 84
      • 6.6.2. Latin America Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 84
      • 6.6.3. Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 86
        • 6.6.3.1. Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 86
      • 6.6.4. Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 87
        • 6.6.4.1. Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 87
      • 6.6.5. Latin America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 88
        • 6.6.5.1. Latin America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 88
      • 6.6.6. Latin America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 89
        • 6.6.6.1. Latin America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 89
      • 6.6.7. Brazil 90
        • 6.6.7.1. Brazil Market size and forecast, 2016-2026 (USD Million) 90
      • 6.6.8. Rest of Latin America 91
        • 6.6.8.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million) 91
    • 6.7. The Middle-East and Africa 92
      • 6.7.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 92
      • 6.7.2. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 92
      • 6.7.3. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 94
        • 6.7.3.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 94
      • 6.7.4. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 95
        • 6.7.4.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 95
      • 6.7.5. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 96
        • 6.7.5.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 96
      • 6.7.6. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 97
        • 6.7.6.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 97
      • 6.7.7. GCC Countries 98
        • 6.7.7.1. GCC Countries Market size and forecast, 2016-2026 (USD Million) 98
      • 6.7.8. South Africa 99
        • 6.7.8.1. South Africa Market size and forecast, 2016-2026 (USD Million) 99
      • 6.7.9. Rest of Middle-East Africa 100
        • 6.7.9.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million) 100
  • Chapter 7. Urinary Tract Infection Therapeutics market - Competitive Landscape 101
    • 7.1. Competitor Market Share - Revenue 101
    • 7.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players 103
    • 7.3. Strategic Development 104
      • 7.3.1. Acquisitions and Mergers 104
      • 7.3.2. New Products 104
      • 7.3.3. Research & Development Activities 104
  • Chapter 8. Company Profiles 105
    • 8.1. Johnson & Johnson Services, Inc. 105
      • 8.1.1. Company Overview 105
      • 8.1.2. Johnson & Johnson Services, Inc. Revenue and Gross Margin 105
      • 8.1.3. Product portfolio 106
      • 8.1.4. Recent initiatives 107
    • 8.2. GlaxoSmithKline 107
      • 8.2.1. Company Overview 107
      • 8.2.2. GlaxoSmithKline Revenue and Gross Margin 107
      • 8.2.3. Product portfolio 108
      • 8.2.4. Recent initiatives 109
    • 8.3. Novartis AG 109
      • 8.3.1. Company Overview 109
      • 8.3.2. Novartis AG Revenue and Gross Margin 109
      • 8.3.3. Product portfolio 110
      • 8.3.4. Recent initiatives 111
    • 8.4. Teva Pharmaceutical Industries Ltd. 111
      • 8.4.1. Company Overview 111
      • 8.4.2. Teva Pharmaceutical Industries Ltd. Revenue and Gross Margin 111
      • 8.4.3. Product portfolio 112
      • 8.4.4. Recent initiatives 113
    • 8.5. Sun Pharmaceutical Industries Ltd. 113
      • 8.5.1. Company Overview 113
      • 8.5.2. Sun Pharmaceutical Industries Ltd. Revenue and Gross Margin 113
      • 8.5.3. Product portfolio 114
      • 8.5.4. Recent initiatives 115
    • 8.6. Pfizer Inc. 115
      • 8.6.1. Company Overview 115
      • 8.6.2. Pfizer Inc. Revenue and Gross Margin 115
      • 8.6.3. Product portfolio 116
      • 8.6.4. Recent initiatives 117
    • 8.7. F. Hoffmann-La Roche Ltd 117
      • 8.7.1. Company Overview 117
      • 8.7.2. F. Hoffmann-La Roche Ltd Revenue and Gross Margin 117
      • 8.7.3. Product portfolio 118
      • 8.7.4. Recent initiatives 119
    • 8.8. C.H. Boehringer Sohn AG & Co.KG 119
      • 8.8.1. Company Overview 119
      • 8.8.2. C.H. Boehringer Sohn AG & Co.KG Revenue and Gross Margin 119
      • 8.8.3. Product portfolio 120
      • 8.8.4. Recent initiatives 121
    • 8.9. Achaogen, Inc. 121
      • 8.9.1. Company Overview 121
      • 8.9.2. Achaogen, Inc. Revenue and Gross Margin 121
      • 8.9.3. Product portfolio 122
      • 8.9.4. Recent initiatives 123
    • 8.10. ALLERGAN 123
      • 8.10.1. Company Overview 123
      • 8.10.2. ALLERGAN Revenue and Gross Margin 123
      • 8.10.3. Product portfolio 124
      • 8.10.4. Recent initiatives 125
    • 8.11. Aquinox 125
      • 8.11.1. Company Overview 125
      • 8.11.2. Aquinox Revenue and Gross Margin 125
      • 8.11.3. Product portfolio 126
      • 8.11.4. Recent initiatives 127
    • 8.12. AstraZeneca 127
      • 8.12.1. Company Overview 127
      • 8.12.2. AstraZeneca Revenue and Gross Margin 127
      • 8.12.3. Product portfolio 128
      • 8.12.4. Recent initiatives 129
    • 8.13. Cipla Inc. 129
      • 8.13.1. Company Overview 129
      • 8.13.2. Cipla Inc. Revenue and Gross Margin 129
      • 8.13.3. Product portfolio 130
      • 8.13.4. Recent initiatives 131
    • 8.14. Bayer AG 131
      • 8.14.1. Company Overview 131
      • 8.14.2. Bayer AG Revenue and Gross Margin 131
      • 8.14.3. Product portfolio 132
      • 8.14.4. Recent initiatives 133
    • 8.15. Dr. Reddy's Laboratories Ltd. 133
      • 8.15.1. Company Overview 133
      • 8.15.2. Dr. Reddy's Laboratories Ltd. Revenue and Gross Margin 133
      • 8.15.3. Product portfolio 134
      • 8.15.4. Recent initiatives 135
    • 8.16. Lipella Pharmaceuticals Inc. 135
      • 8.16.1. Company Overview 135
      • 8.16.2. Lipella Pharmaceuticals Inc. Revenue and Gross Margin 135
      • 8.16.3. Product portfolio 136
      • 8.16.4. Recent initiatives 137
    • 8.17. MediciNova, Inc. 137
      • 8.17.1. Company Overview 137
      • 8.17.2. MediciNova, Inc. Revenue and Gross Margin 137
      • 8.17.3. Product portfolio 138
      • 8.17.4. Recent initiatives 139
    • 8.18. MerLion Pharmaceuticals GmbH 139
      • 8.18.1. Company Overview 139
      • 8.18.2. MerLion Pharmaceuticals GmbH Revenue and Gross Margin 139
      • 8.18.3. Product portfolio 140
      • 8.18.4. Recent initiatives 141
    • 8.19. Mylan N.V. 141
      • 8.19.1. Company Overview 141
      • 8.19.2. Mylan N.V. Revenue and Gross Margin 141
      • 8.19.3. Product portfolio 142
      • 8.19.4. Recent initiatives 143
    • 8.20. Novo Nordisk A/S 143
      • 8.20.1. Company Overview 143
      • 8.20.2. Novo Nordisk A/S Revenue and Gross Margin 143
      • 8.20.3. Product portfolio 144
      • 8.20.4. Recent initiatives 145
    • 8.21. Shionogi Inc. 145
      • 8.21.1. Company Overview 145
      • 8.21.2. Shionogi Inc. Revenue and Gross Margin 145
      • 8.21.3. Product portfolio 146
      • 8.21.4. Recent initiatives 147
    • 8.22. Urigen 147
      • 8.22.1. Company Overview 147
      • 8.22.2. Urigen Revenue and Gross Margin 147
      • 8.22.3. Product portfolio 148
      • 8.22.4. Recent initiatives 149
    • 8.23. Zavante Therapeutics, Inc. 149
      • 8.23.1. Company Overview 149
      • 8.23.2. Zavante Therapeutics, Inc. Revenue and Gross Margin 149
      • 8.23.3. Product portfolio 150
      • 8.23.4. Recent initiatives 151
  • Chapter 9. Urinary Tract Infection Therapeutics ' Industry Analysis 152
    • 9.1. Urinary Tract Infection Therapeutics Market - Key Trends 152
      • 9.1.1. Market Drivers 153
      • 9.1.2. Market Restraints 153
      • 9.1.3. Market Opportunities 154
    • 9.2. Value Chain Analysis 155
    • 9.3. Technology Roadmap and Timeline 156
    • 9.4. Urinary Tract Infection Therapeutics Market - Attractiveness Analysis 157
      • 9.4.1. By Age Group 157
      • 9.4.2. By Indication 157
      • 9.4.3. By Drug Type 158
      • 9.4.4. By Distribution Channel 159
      • 9.4.5. By Region 160
  • Chapter 10. Marketing Strategy Analysis, Distributors 161
    • 10.1. Marketing Channel 161
    • 10.2. Direct Marketing 162
    • 10.3. Indirect Marketing 162
    • 10.4. Marketing Channel Development Trend 162
    • 10.5. Economic/Political Environmental Change 163
  • Chapter 11. Report Conclusion 164
  • Chapter 12. Research Approach & Methodology 165
    • 12.1. Report Description 165
    • 12.2. Research Scope 166
    • 12.3. Research Methodology 166
      • 12.3.1. Secondary Research 167
      • 12.3.2. Primary Research 168
      • 12.3.3. Models 169
        • 12.3.3.1. Company Share Analysis Model 169
        • 12.3.3.2. Revenue Based Modeling 170
        • 12.3.3.3. Research Limitations 170

List of Figures

FIG. 1 Global Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 28
FIG. 2 Global Urinary Tract Infection Therapeutics Market Share, by Age Group, 2018 & 2025 (USD Million) 29
FIG. 3 Global Adults Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 31
FIG. 4 Global Elderly Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 32
FIG. 5 Global Children Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 33
FIG. 6 Global Urinary Tract Infection Therapeutics Market Share, by Indication, 2018 & 2025 (USD Million) 34
FIG. 7 Global Uncomplicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 35
FIG. 8 Global Recurrent UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 36
FIG. 9 Global Complicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 37
FIG. 10 Global CA (Catheter Associated) UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 38
FIG. 11 Global Urinary Tract Infection Therapeutics Market Share, by Drug Type, 2018 & 2025 (USD Million) 39
FIG. 12 Global Quinolones Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 41
FIG. 13 Global Azoles & Amphotericin B Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 42
FIG. 14 Global Aminoglycoside Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 43
FIG. 15 Global Penicillin & Combinations Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 44
FIG. 16 Global Cephalosporin Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 45
FIG. 17 Global Nitrofurans Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 46
FIG. 18 Global Others Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 47
FIG. 19 Global Urinary Tract Infection Therapeutics Market Share, by Distribution Channel, 2018 & 2025 (USD Million) 48
FIG. 20 Global Hospital Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 49
FIG. 21 Global Retail Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 50
FIG. 22 Global E-commerce Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 51
FIG. 23 Global Urinary Tract Infection Therapeutics Market Share, by Region, 2018 & 2025 52
FIG. 24 North America Urinary Tract Infection Therapeutics Market, 2016-2026 54
FIG. 25 U.S. Urinary Tract Infection Therapeutics Market, 2016-2026 60
FIG. 26 Rest of North America Urinary Tract Infection Therapeutics Market, 2016-2026 61
FIG. 27 Europe Urinary Tract Infection Therapeutics Market, 2016-2026 62
FIG. 28 Germany Urinary Tract Infection Therapeutics Market, 2016-2026 68
FIG. 29 France Urinary Tract Infection Therapeutics Market, 2016-2026 69
FIG. 30 U.K. Urinary Tract Infection Therapeutics Market, 2016-2026 70
FIG. 31 Italy Urinary Tract Infection Therapeutics Market, 2016-2026 71
FIG. 32 Spain Urinary Tract Infection Therapeutics Market, 2016-2026 72
FIG. 33 Rest of Europe Urinary Tract Infection Therapeutics Market, 2016-2026 73
FIG. 34 Asia Pacific Urinary Tract Infection Therapeutics Market, 2016-2026 74
FIG. 35 China Urinary Tract Infection Therapeutics Market, 2016-2026 80
FIG. 36 Japan Urinary Tract Infection Therapeutics Market, 2016-2026 81
FIG. 37 India Urinary Tract Infection Therapeutics Market, 2016-2026 82
FIG. 38 South-East Asia Urinary Tract Infection Therapeutics Market, 2016-2026 83
FIG. 39 Rest of Asia Pacific Urinary Tract Infection Therapeutics Market, 2016-2026 84
FIG. 40 Latin America Urinary Tract Infection Therapeutics Market, 2016-2026 85
FIG. 41 Brazil Urinary Tract Infection Therapeutics Market, 2016-2026 91
FIG. 42 Rest of Latin America Urinary Tract Infection Therapeutics Market, 2016-2026 92
FIG. 43 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, 2016-2026 93
FIG. 44 GCC Countries Urinary Tract Infection Therapeutics Market, 2016-2026 99
FIG. 45 South Africa Urinary Tract Infection Therapeutics Market, 2016-2026 100
FIG. 46 Rest of Middle-East Africa Urinary Tract Infection Therapeutics Market, 2016-2026 101
FIG. 47 Competitor Market Share – Revenue 102
FIG. 48 Johnson & Johnson Services, Inc. Revenue and Growth Rate 107
FIG. 49 Johnson & Johnson Services, Inc. Market Share 107
FIG. 50 GlaxoSmithKline Revenue and Growth Rate 109
FIG. 51 GlaxoSmithKline Market Share 109
FIG. 52 Novartis AG Revenue and Growth Rate 111
FIG. 53 Novartis AG Market Share 111
FIG. 54 Teva Pharmaceutical Industries Ltd. Revenue and Growth Rate 113
FIG. 55 Teva Pharmaceutical Industries Ltd. Market Share 113
FIG. 56 Sun Pharmaceutical Industries Ltd. Revenue and Growth Rate 115
FIG. 57 Sun Pharmaceutical Industries Ltd. Market Share 115
FIG. 58 Pfizer Inc. Revenue and Growth Rate 117
FIG. 59 Pfizer Inc. Market Share 117
FIG. 60 F. Hoffmann-La Roche Ltd Revenue and Growth Rate 119
FIG. 61 F. Hoffmann-La Roche Ltd Market Share 119
FIG. 62 C.H. Boehringer Sohn AG & Co.KG Revenue and Growth Rate 121
FIG. 63 C.H. Boehringer Sohn AG & Co.KG Market Share 121
FIG. 64 Achaogen, Inc. Revenue and Growth Rate 123
FIG. 65 Achaogen, Inc. Market Share 123
FIG. 66 ALLERGAN Revenue and Growth Rate 125
FIG. 67 ALLERGAN Market Share 125
FIG. 68 Aquinox Revenue and Growth Rate 127
FIG. 69 Aquinox Market Share 127
FIG. 70 AstraZeneca Revenue and Growth Rate 129
FIG. 71 AstraZeneca Market Share 129
FIG. 72 Cipla Inc. Revenue and Growth Rate 131
FIG. 73 Cipla Inc. Market Share 131
FIG. 74 Bayer AG Revenue and Growth Rate 133
FIG. 75 Bayer AG Market Share 133
FIG. 76 Dr. Reddy's Laboratories Ltd. Revenue and Growth Rate 135
FIG. 77 Dr. Reddy's Laboratories Ltd. Market Share 135
FIG. 78 Lipella Pharmaceuticals Inc. Revenue and Growth Rate 137
FIG. 79 Lipella Pharmaceuticals Inc. Market Share 137
FIG. 80 MediciNova, Inc. Revenue and Growth Rate 139
FIG. 81 MediciNova, Inc. Market Share 139
FIG. 82 MerLion Pharmaceuticals GmbH Revenue and Growth Rate 141
FIG. 83 MerLion Pharmaceuticals GmbH Market Share 141
FIG. 84 Mylan N.V. Revenue and Growth Rate 143
FIG. 85 Mylan N.V. Market Share 143
FIG. 86 Novo Nordisk A/S Revenue and Growth Rate 145
FIG. 87 Novo Nordisk A/S Market Share 145
FIG. 88 Shionogi Inc. Revenue and Growth Rate 147
FIG. 89 Shionogi Inc. Market Share 147
FIG. 90 Urigen Revenue and Growth Rate 149
FIG. 91 Urigen Market Share 149
FIG. 92 Zavante Therapeutics, Inc. Revenue and Growth Rate 151
FIG. 93 Zavante Therapeutics, Inc. Market Share 151
FIG. 94 Market Dynamics 153
FIG. 95 Global Urinary Tract Infection Therapeutics – Value Chain Analysis 156
FIG. 96 Technology Roadmap and Timeline 157
FIG. 97 Market Attractiveness Analysis – By Age Group 158
FIG. 98 Market Attractiveness Analysis – By Indication 159
FIG. 99 Market Attractiveness Analysis – By Drug Type 159
FIG. 100 Market Attractiveness Analysis – By Distribution Channel 160
FIG. 101 Market Attractiveness Analysis – By Region 161
FIG. 102 Market Channel 162
FIG. 103 Marketing Channel Development Trend 163
FIG. 104 Growth in World Gross Product, 2008-2018 164


List of Tables

TABLE 1 Global Urinary Tract Infection Therapeutics Market, 2018 & 2025 (USD Million) 27
TABLE 2 Global Urinary Tract Infection Therapeutics market, by Age Group, 2016-2026 (USD Million) 29
TABLE 3 Global Urinary Tract Infection Therapeutics market, by Indication, 2016-2026 (USD Million) 34
TABLE 4 Global Urinary Tract Infection Therapeutics market, by Drug Type, 2016-2026 (USD Million) 39
TABLE 5 Global Urinary Tract Infection Therapeutics market, by Distribution Channel, 2016-2026 (USD Million) 48
TABLE 6 Global Urinary Tract Infection Therapeutics market, by Region, 2016-2026 (USD Million) 52
TABLE 7 North America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 56
TABLE 8 North America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 57
TABLE 9 North America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 58
TABLE 10 North America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 59
TABLE 11 Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 64
TABLE 12 Europe Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 65
TABLE 13 Europe Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 66
TABLE 14 Europe Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 67
TABLE 15 Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 76
TABLE 16 Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 77
TABLE 17 Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 78
TABLE 18 Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 79
TABLE 19 Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 87
TABLE 20 Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 88
TABLE 21 Latin America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 89
TABLE 22 Latin America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 90
TABLE 23 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 95
TABLE 24 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 96
TABLE 25 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 97
TABLE 26 The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 98
TABLE 27 Global Urinary Tract Infection Therapeutics Market - Company Revenue Analysis 2016-2018 (USD Million) 102
TABLE 28 Global Urinary Tract Infection Therapeutics Market - Company Revenue Share Analysis 2016-2018 (%) 104
TABLE 29 Acquisitions and Mergers 105
TABLE 30 New Product/Service Launch 105
TABLE 31 Research & Development Activities 105
TABLE 32 Market Drivers 154
TABLE 33 Market Restraints 154
TABLE 34 Market Opportunities 155

Industry Major Market Players

  • Zavante Therapeutics,
  • Urigen,
  • Shionogi,
  • Novo Nordisk,
  • Mylan,
  • MerLion Pharmaceuticals,
  • MediciNova,
  • Lipella Pharmaceuticals,
  • Dr. Reddy’s Laboratories,
  • Bayer,
  • Cipla,
  • AstraZeneca,
  • Aquinox,
  • ALLERGAN,
  • Achaogen,
  • C.H. Boehringer Sohn,
  • F. Hoffmann-La Roche,
  • Pfizer,
  • Sun Pharmaceutical Industries,
  • Teva Pharmaceutical Industries,
  • Novartis,
  • GlaxoSmithKlineJohnson & Johnson
     

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2020 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions